Stock Events

Stock Events

Cardax 

$0.000100
4
+$0.00+0%Thursday 20:00

Statistics

Day High
0.000001
Day Low
0.000001
52W High
0.0001
52W Low
0.000001
Volume
1
Avg. Volume
17
Mkt Cap
80.3
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Nov 14Expected
Q3 2020
Q1 2021
Q2 2021
Q3 2021
Q1 2022
Q2 2022
Q3 2022
-1.3
-0.87
-0.43
0
Expected EPS
0
Actual EPS
0

Financials

-938.03%Profit Margin
Unprofitable
2015
2016
2017
2018
2019
2020
539,000Revenue
-5.06MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap94.23B
GlaxoSmithKline plc is a global healthcare company that competes with Cardax in the development and commercialization of pharmaceuticals and healthcare products, including those in the inflammation and cardiovascular sectors.
AMGEN
AMGN
Mkt Cap217.9B
Amgen Inc. is a biopharmaceutical company that competes with Cardax in the research and development of treatments for cardiovascular diseases and inflammation.
Pfizer
PFE
Mkt Cap158.45B
Pfizer Inc. is a global pharmaceutical corporation that competes with Cardax in the development and marketing of drugs and vaccines for a wide range of conditions, including those related to cardiovascular health.
Merck
MRK
Mkt Cap356.01B
Merck & Co., Inc. is a global healthcare company that competes with Cardax in the development of pharmaceuticals and vaccines, with a focus on cardiovascular diseases among others.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie Inc. is a biopharmaceutical company that competes with Cardax in the development of therapies for various conditions, including cardiovascular and inflammatory diseases.
Novartis
NVS
Mkt Cap268B
Novartis AG is a global healthcare company that competes with Cardax in the development and marketing of products in the cardiovascular and inflammation areas.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson is a diversified healthcare company that competes with Cardax through its pharmaceutical division in developing treatments for cardiovascular and inflammatory diseases.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol-Myers Squibb Company is a global biopharmaceutical company that competes with Cardax in the development of cardiovascular and anti-inflammatory drugs.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly and Company is a global pharmaceutical company that competes with Cardax in the development and commercialization of drugs for cardiovascular and inflammatory conditions.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca PLC is a global, science-led biopharmaceutical business that competes with Cardax in the development of medicines for cardiovascular and inflammatory diseases.

About

Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity. This product is primarily distributed through online sales and wholesale channels. The company is also progressing two pharmaceutical candidates: CDX-101, an astaxanthin-derived drug candidate intended to address cardiovascular inflammation and dyslipidemia, with a primary focus on severe hypertriglyceridemia; and CDX-301, a zeaxanthin-based pharmaceutical currently under development for macular degeneration. Cardax, Inc. maintains its headquarters in Honolulu, Hawaii.
Show More
CEO
David G. Watumull
Employees
10
Country
United States
ISIN
US14141D2018

Listings

OTC Link
US
CDXI

0 Comments

Share your thoughts

FAQs

What is Cardax stock price today?▼
The current price of CDXI is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Cardax stock price performance more closely on the chart.
What is Cardax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Cardax stocks are traded under the ticker CDXI.
Is Cardax stock price growing?▼
CDXI stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Cardax has showed a +0% increase.
What is Cardax market cap?▼
Today Cardax has the market capitalization of 80.3
What were Cardax earnings last quarter?▼
CDXI earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cardax revenue for the last year?▼
Cardax revenue for the last year amounts to 539,000 USD.
What is Cardax net income for the last year?▼
CDXI net income for the last year is -5.06M USD.
How many employees does Cardax have?▼
As of November 1, 2026, the company has 10 employees.
In which sector is Cardax located?▼
Cardax operates in the Health & Wellness sector.
When did Cardax complete a stock split?▼
The last stock split for Cardax was on January 15, 2020 with a ratio of 1:200.
Where is Cardax headquartered?▼
Cardax is headquartered in Honolulu, United States.